<1% incidence of grade 3-4 hyperbilirubinemia
and no jaundice or scleral icterus1
PI-experienced patients
•
No grade 3-4 hyperbilirubinemia and no jaundice or scleral icterus1
•
Treatment with LEXIVA/r has resulted in increases in the concentration of triglycerides. Triglyceride and cholesterol testing should be performed prior to initiating therapy with LEXIVA and at periodic intervals during therapy.
•
Caution should be exercised when administering LEXIVA to patients with hepatic impairment, including those with hepatitis B or C or marked elevation in transaminases prior to treatment. Increased AST/ALT monitoring should be considered in these patients.
